Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Ranjbar
 
IRCT20200204046369N1
RCTmethylprednisolonedexamethasoneCOVID 19 hospitalizedsome concern
44/42 suggested
  • inconclusive 60 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 64 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
Metcovid
 
NCT04343729
RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
209/207 inconclusive
  • inconclusive 8 % decrease in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
Tang X
 
NCT04273321
RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
43/43 suggested
  • inconclusive 0 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 78 % increase in viral clearance ,viral clearance (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

Steroids-SARI
 
NCT04244591
RCTmethylprednisolonestandard of careCOVID-19 severe or criticallysome concern
24/23 inconclusive
    1 study excluded by filtering options (1 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).